Aβ immunotherapy for Alzheimer's disease

Brain and Nerve

Volumn 65, Issue 4, 2013, Pages 461-468

  Sakai, Kenji ^a,b   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Amyloid; Amyloid (A ); Cerebral amyloid angiopathy; Immunotherapy; Meningoencephalitis

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; BAPINEUZUMAB; SOLANEZUMAB; TAU PROTEIN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ARTICLE; BRAIN HEMORRHAGE; COGNITION; HUMAN; LYMPHATIC DRAINAGE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN PHOSPHORYLATION; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY;

EID: 84876336245     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Duyckaerts C, Dickson D: Neuropathology of Alzheimer's disease and its variants. Dickson DW, Weller RO(eds): Neurodegeneration: the molecular pathology of dementia and movement disorders. 2nd ed, Wiley-Blackewll, Chichester, 2011, pp62-91
2. Knopman D: Clinical aspects of Alzheimer's disease. Dickson DW, Weller RO(eds): Neurodegeneration: the molecular pathology of dementia and movement disorders. 2nd ed, Wiley-Blackewll, Chichester, 2011, pp39-50
3. Weller RO, Djuanda E, Yow HY, Carare RO: Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol 117: 1-14, 2009
4. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, et al: Abeta-degrading enzyme in Alzheimer's disease. Brain Pathol 18: 240-252, 2008
5. Bell RD, Zlokovic BV: Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118: 103-113, 2009
6. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356, 2002 (Pubitemid 34790756)
7. Masters CL, Beyreuther K: Amyloid-β production. Dickson DW, Weller RO(eds): Neurodegeneration: the molecular pathology of dementia and movement disorders. 2nd ed, Chichester, Wiley-Blackewll, Chichester, 2011, pp92-96
8. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, et al: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119-128, 2010
9. Delrieu J, Ousset PJ, Caillaud C, Vellas B: Clinical trials in Alzheimer's disease: immunotherapy approaches. J Neurochem 120 (Suppl 1): 186-193, 2012
10. Wang W, Fan L, Xu D, Wen Z, Yu R, et al: Immunotherapy for Alzheimer's disease. Acta Biochim Biophys Sin 44: 807-814, 2012
11. Morgan D: Immunotherapy for Alzheimer's disease. J Intern Med 269: 54-63, 2011
12. McGeer PL, McGeer EG: Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 22: 799-809, 2001 (Pubitemid 34066546)
13. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, et al: Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98: 8850-8855, 2001 (Pubitemid 32678116)
14. Solomon B, Koppel R, Hanan E, Katzav T: Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A 93: 452-455, 1996 (Pubitemid 26038175)
15. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177, 1999 (Pubitemid 29327547)
16. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang y, et al: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982, 2000 (Pubitemid 32101644)
17. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, et al: Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7: 369-372, 2001 (Pubitemid 32224356)
18. Sigurdsson EM: Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis 15: 157-168, 2008
19. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM: Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118: 658-667, 2011
20. Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, et al: Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 63: 1459-1467, 2006 (Pubitemid 44547559)
21. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, et al: Evaluation of the safety and immunogenicity of synthetic Aβ342 (AN1792) in patients with AD. Neurology 64: 94-101, 2005 (Pubitemid 40082943)
22. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, et al: Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562, 2005 (Pubitemid 40617691)
23. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, et al: Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61: 46-54, 2003 (Pubitemid 36818745)
24. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, et al: Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372: 216-223, 2008 (Pubitemid 351978111)
25. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, et al: Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 6: 144-151, 2009
26. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, et al: Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64: 1563-1572, 2005 (Pubitemid 40617692)
27. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, et al: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9: 448-452, 2003 (Pubitemid 36460079)
28. Nicoll JAR, Barton E, Boche D, Neal JW, Ferrer I, et al: Aβ species removal after Aβ42 immunization. J Neuropathol Exp Neurol 65: 1040-1048, 2006
29. Boche D, Zotova E, Weller RO, Love S, Neal JW, et al: Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain. Brain 131: 3299-3310, 2008
30. Boche D, Donald J, Love S, Harris S, Neal JW, et al: Reduction of aggregated tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer's disease. Acta Neuropathol 120: 13-20, 2010
31. Boche D, Denham N, Holmes C, Nicoll JAR: Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol 120: 369-384, 2010
32. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, et al: Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11: 597-604, 2012
33. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, et al: A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73: 2061-2070, 2009
34. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, et al: Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 69: 1002-1010, 2012
35. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, et al: 11C-Pib PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9: 363-372, 2010
36. Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, et al: Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33: 67-73, 2010
37. Samadi H, Sultzer D: Solanezumab for Alzheimer's disease. Expert Opin Biol Ther 11: 787-798, 2011
38. Dodel RC, Du Y, Depboylu C, Hampel H, Frölich L, et al: Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75: 1472-1474, 2004 (Pubitemid 39279821)
39. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, et al: 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 30: 1728-1736, 2009
40. Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, et al: A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 24: 198-203, 2010
41. Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, et al: Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's association research roundtable workgroup. Alzheimers Dement 7: 367-385, 2011
42. Sperling R, Salloway S, Brooks D, Tampieri D, Barakos J, et al: Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 11: 241-249 2012
43. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, et al: Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298: 1379, 2002 (Pubitemid 35346131)